Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lyophilized Injectable Drugs Market

Lyophilized Injectable Drugs Market Size

Report ID: GMI5371
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Lyophilized Injectable Drugs Market Size

Lyophilized Injectable Drugs Market size reached over USD 280 billion in 2022 and is poised to record 13.5% CAGR by 2032 attributed to the increasing research, development, as well as commercialization of novel drugs to cater to varied disease treatment.

To get key market trends

Download Free Sample

Numerous companies are collaborating with several other players for fastening their discovery process and boosting the product development capabilities of the organization. Several pharmaceutical firms are also harnessing external sources of technologies and R&D activities to bring innovations. For instance, Pfizer, in May 2022, established its drug R&D center in India for developing active pharmaceutical ingredients as well as finished dosage forms, such as lyophilized injectables. The increasing collaboration of contract research manufacturing services (CRAMS) with major pharmaceutical companies for scaling up their operational capabilities for injectable drugs.

Lyophilized Injectable Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2022
Lyophilized Injectable Drugs Market Size in 2022:	USD 280.6 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	13.5%
2032 Value Projection:	USD 987.3 Billion
Historical Data for:	2018 to 2022
No. of Pages:	279
Tables, Charts & Figures:	480
Segments covered:	Drug type, Indication, Type of delivery, Packaging, Distribution channel, and Region
Growth Drivers:	Increasing prevalence of chronic diseases globally Growing research and development activities in the industry Increasing number of product approvals for lyophilized injectable drugs Technological advancements in lyophilized injectable drugs delivery system
Pitfalls & Challenges:	Substantial number of product recalls of lyophilized drugs High costs associated with the manufacturing process

Learn more about the key segments shaping this market

Download Free Sample

The rising costs associated with the manufacturing process, particularly the integration of innovative technologies into lyophilized injectables drug delivery systems will act as a restraint for the business gains. The escalating prices related to the development of novel technologies, including dual chamber syringes, cartridges, and others.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lyophilized injectable drugs industry size was more than USD 280 billion in 2022 and will record 13.5% CAGR by 2032 ascribing to the increasing research, development, as well as commercialization of novel drugs to cater to varied disease treatment.

Anti-infective lyophilized injectable drugs market size is anticipated to exceed USD 311 billion by 2032 due to the surging incidences of various infectious diseases, such as HIV, herpes simplex virus, influenza, and hepatitis virus.

North America held over 47% of the industry share in 2022 owing to the rising prevalence of chronic diseases and the surging need for well-established healthcare infrastructure in the region.

Some of the leading lyophilized injectable drugs industry players are Novo Nordisk A/S, Sanofi, Aurobindo Pharmaceuticals, Fresenius SE & Co. KGaA (Fresenius Kabi), Merck & Co., Inc, Zydus Group, Vetter Pharma, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services.